Login / Signup

A novel ryanodine receptor 2 inhibitor, M201-A, enhances natriuresis, renal function and lusi-inotropic actions: Preclinical and phase I study.

Noboru KanekoChristopher M LoughreyGodfrey L SmithRyuko MatsudaTomoko HasunumaPatric B MarkMasashi TodaMakoto ShinozakiNaoyuki OtaniScott KayleyAna Da Silva CostaTamara P MartinSara DobiPriyanka SaxenaKen ShimamotoTetsuya IshikawaRyuichi KambayashiAlexandra RiddellElspeth B ElliottCharlotte S McCarrollToshiya SakaiYamano MitsuhisaSayuri HiranoTakeshi KitaiKengo KusanoYuko InoueMasahiko NakamuraMigaku KikuchiShigeru ToyodaIsao TaguchiToshihiko FujiwaraAtsushi SugiyamaYuji KumagaiKunio Iwata
Published in: British journal of pharmacology (2024)
leak via RyR2, improved cardiac lusi-inotropic effects in rats, and enhanced natriuresis and renal function in humans. These findings suggest that this drug may offer a potential new treatment option for chronic kidney disease and heart failure.
Keyphrases
  • chronic kidney disease
  • heart failure
  • left ventricular
  • end stage renal disease
  • emergency department
  • cell therapy
  • atrial fibrillation
  • stem cells
  • bone marrow
  • combination therapy
  • climate change
  • replacement therapy